Key result
In-silico modeling links sacubitril/valsartan heart failure pathways to potential macular degeneration risk.
Why the study?
Understanding the diverse mechanisms of action of sacubitril/valsartan and their association with potential adverse effects like macular degeneration is important for future personalized medicine.
Does sacubitril/valsartan use in heart failure associate with macular degeneration mechanisms in in-silico models?
Does sacubitril/valsartan use in heart failure associate with macular degeneration mechanisms in in-silico models?
In-silico modeling suggests a theoretical link between the mechanisms of sacubitril/valsartan efficacy in heart failure and the development of macular degeneration, proposing 30 biomarkers for further study.
No clinical action warranted from in-silico link; leaves open mechanistic overlap between sacubitril/valsartan efficacy and macular degeneration for biomarker validation.
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients. Data and accession to software are available at http://sbi.upf.edu/data/tpms/.
No takes yet. Share an insight, caveat, or question.
Jorba et al. (2020) studied Heart failure. Sacubitril/valsartan was evaluated on Relationship between sacubitril/valsartan and heart failure, and association with macular degeneration. In-silico modeling of sacubitril/valsartan identified mechanisms of action associated with good heart failure response that could also be linked to macular degeneration development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: